Current
Neuro-Oncology


Volume 24 Number 17
15 september 2022


Home > Publications > Current Neuro-Oncology > Volume 24, Year 2022 > Number 17, 15 September






Chen X, Zhang Y, Zhao Q, Bai L, Chen X, Zhou Z.
Management of dermatologic adverse events associated with tumor treating fields in patients with glioblastoma multiforme: A 27-case series.
Asia Pac J Oncol Nurs. 2022 Jun 2, 2022;9(8):100095. doi: 10.1016/j.apjon.2022.100095. PMID: 36060271. Observational study.




Kara B, Danyeli AE, Öztürk M, Ertan K, Köksal Y.
A pediatric bithalamic high grade glioma with concomitant H3K27M and EGFR mutations.
Turk J Pediatr. 2022 Jul-Aug, 2022;64(4):754-758
. doi: 10.24953/turkjped.2021.1140. PMID: 36082650. Case report.




Mizuno R, Homma T, Adachi JI, Mishima K, Suzuki T, Shirahata M, Nishikawa R, Atushi S.
True anaplastic oligoastrocytoma with dual genotype: illustrative case.
J Neurosurg Case Lessons. 2022 Jul 18, 2022;4(3):CASE22146. doi: 10.3171/CASE22146. PMID: 36046704. Case report.



*

Goldman S, Margol A, Hwang EI, Tanaka K, Suchorska B, Crawford JR, Kesari S.
Safety of Tumor Treating Fields (TTFields) therapy in pediatric patients with malignant brain tumors: Post-marketing surveillance data.
Front Oncol. 2022 Jul 29, 2022;12:958637. doi: 10.3389/fonc.2022.958637. PMID: 36072789. Observational study.




She L, Su L, Liu C.
Bevacizumab combined with re-irradiation in recurrent glioblastoma.
Front Oncol. 2022 Aug 4, 2022;12:961014. doi: 10.3389/fonc.2022.961014. PMID: 36046037. Observational study.




Ran Z, Yang J, Liu Y, Chen X, Ma Z, Wu S, Huang Y, Song Y, Gu Y, Zhao S, Fa M, Lu J, Chen Q, Cao Z, Li X, Sun S, Yang T.
GlioMarker: An integrated database for knowledge exploration of diagnostic biomarkers in gliomas.
Front Oncol. 2022 Aug 11, 2022;12:792055. doi: 10.3389/fonc.2022.792055. PMID: 36081550. Observational study.



*

El-Abtah ME, Talati P, Fu M, Chun B, Clark P, Peters A, Ranasinghe A, He J, Rapalino O, Batchelor TT, Gilberto Gonzalez R, Curry WT, Dietrich J, Gerstner ER, Ratai EM.
Magnetic resonance spectroscopy outperforms perfusion in distinguishing between pseudoprogression and disease progression in patients with glioblastoma.
Neurooncol Adv. 2022 Aug 15, 2022;4(1):vdac128. doi: 10.1093/noajnl/vdac128. PMID: 36071927. Observational study.




Li J, Yang W, Yuan Y, Zuo M, Li T, Wang Z, Liu Y.
Preoperative Naples prognostic score is a reliable prognostic indicator for newly diagnosed glioblastoma patients.
Front Oncol. 2022 Aug 16, 2022;12:775430
. doi: 10.3389/fonc.2022.775430. PMID: 36052263. Observational study.



*

Yang G, Fang Y, Zhou M, Li W, Dong D, Chen J, Da Y, Wang K, Li X, Zhang X, Ma T, Shen G.
Case report: The effective response to pembrolizumab in combination with bevacizumab in the treatment of a recurrent glioblastoma with multiple extracranial metastases.
Front Oncol. 2022 Aug 16, 2022;12:948933. doi: 10.3389/fonc.2022.948933. PMID: 36052225. Case report.




Zhang HH, Du XJ, Deng ML, Zheng L, Yao DC, Wang ZQ, Yang QY, Wu SX.
Apatinib for recurrent/progressive glioblastoma multiforme: A salvage option.
Front Pharmacol. 2022 Aug 17, 2022;13:969565. doi: 10.3389/fphar.2022.969565. PMID: 36060005. Observational study.




Łysiak M, Das J, Malmström A, Söderkvist P.
Methylation associated with long- or short-term survival in glioblastoma patients from the Nordic phase 3 trial.
Front Genet. 2022 Aug 25, 2022;13:934519
. doi: 10.3389/fgene.2022.934519. PMID: 36092918. Observational study.



*

Tzaridis T, Weller J, Bachurski D, Shakeri F, Schaub C, Hau P, Buness A, Schlegel U, Steinbach JP, Seidel C, Goldbrunner R, Schäfer N, Wechsler-Reya RJ, Hallek M, Scheffler B, Glas M, Haeberle L, Herrlinger U, Coch C, Reiners KS, Hartmann G.
A novel serum extracellular vesicle protein signature to monitor glioblastoma tumor progression.
Int J Cancer. 2022 Aug 27. doi: 10.1002/ijc.34261. PMID: 36054558. Laboratory investigation.




Zong WF, Liu C, Zhang Y, Zhang SJ, Qu WS, Luo X.
Identification of a Signature for Predicting Prognosis and Immunotherapy Response in Patients with Glioma.
J Oncol. 2022 Aug 29, 2022;2022:8615949. doi: 10.1155/2022/8615949. PMID: 36072978. Laboratory investigation.




Ioakeim-Ioannidou M, Giantsoudi D, Niemierko A, Sethi R, Kim DW, Yock TI, Tarbell NJ, Simeone FJ, MacDonald SM.
Effects of Proton Craniospinal Radiation on Vertebral Body Growth Retardation in Children.
Int J Radiat Oncol Biol Phys. 2022 Aug 30, 2022:S0360-3016(22)03212-6. doi: 10.1016/j.ijrobp.2022.08.055. PMID: 36055432. Observational study.



*

Ohno M, Kitanaka C, Miyakita Y, Tanaka S, Sonoda Y, Mishima K, Ishikawa E, Takahashi M, Yanagisawa S, Ohashi K, Nagane M, Narita Y.
Metformin with Temozolomide for Newly Diagnosed Glioblastoma: Results of Phase I Study and a Brief Review of Relevant Studies.
Cancers (Basel). 2022 Aug 30, 2022;14(17):4222. doi: 10.3390/cancers14174222. PMID: 36077758. Interventional study and Review.




Le HT, Staelens M, Lazzari D, Chan G, Tuszyński JA.
Real-Time Monitoring of the Effect of Tumour-Treating Fields on Cell Division Using Live-Cell Imaging.
Cells. 2022 Aug 31, 2022;11(17):2712. doi: 10.3390/cells11172712. PMID: 36078119. Laboratory investigation.



*

Rodríguez-Morales J, Guartazaca-Guerrero S, Rizo-Téllez SA, Viurcos-Sanabria R, Barrón EV, Hernández-Valencia AF, Nava P, Escobedo G, Carrillo-Ruiz JD, Méndez-García LA.
Blood-brain Barrier Damage is Pivotal for SARS-CoV-2 Infection to the Central Nervous System.
Exp Neurobiol. 2022 Aug 31, 2022;31(4):270-276. doi: 10.5607/en21049. PMID: 36050226. Case report.




Czech C, Chen A, Morgan KP, Zamora C, El-Refai S, Poynter N, Khagi S.
Response to Selpercatinib in a Patient With Recurrent Glioblastoma and RET Amplification.
J Natl Compr Canc Netw. 2022 Sep, 2022;20(9):966-971. doi: 10.6004/jnccn.2022.7030. PMID: 36075388. Case report.




Huang J, Chan SC, Lok V, Zhang L, Lin X, Lucero-Prisno DE, Xu W, Zheng ZJ, Elcarte E, Withers M, Wong MCS; NCD Global Health Research Group, Association of Pacific Rim Universities (APRU).
Disease Burden, Risk Factors, and Trends of Primary Central Nervous System (CNS) Cancer: a global study of registries data.
Neuro Oncol. 2022 Sep 1, 2022:noac213. doi: 10.1093/neuonc/noac213. PMID: 36048182. Observational study˰




Iannó MF, Biassoni V, Schiavello E, Carenzo A, Boschetti L, Gandola L, Diletto B, Marchesi E, Vegetti C, Molla A, Kramm CM, van Vuurden DG, Gasparini P, Gianno F, Giangaspero F, Modena P, Bison B, Anichini A, Vennarini S, Pignoli E, Massimino M, De Cecco L.
A microRNA Prognostic Signature in Patients with Diffuse Intrinsic Pontine Gliomas through Non-Invasive Liquid Biopsy.
Cancers (Basel). 2022 Sep 2, 2022;14(17):4307. doi: 10.3390/cancers14174307. PMID: 36077842. Laboratory investigation.




Shidoh S, Savjani RR, Cho NS, Ullman HE, Hagiwara A, Raymond C, Lai A, Nghiemphu PL, Liau LM, Pope WB, Cloughesy TF, Kaprealian TB, Salamon N, Ellingson BM.
Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation.
J Neurooncol. 2022 Sep 2. doi: 10.1007/s11060-022-04123-3. PMID: 36053452. Observational study.




Snyder MH, Yu-Der Wang A, Ampie L, Sarathy D, Chatrath A, Asthagiri AR, Shaffrey CI, Smith JS, Shaffrey ME, Yen CP, Buchholz AL, Syed HR, Kryzanski J, Wu JK, Heilman CB.
Primary Spinal Cord Astrocytomas: Two Center Clinical Experience of Low- and High-grade Lesions.
World Neurosurg. 2022 Sep 5, 2022:S1878-8750(22)01239-6. doi: 10.1016/j.wneu.2022.08.130. PMID: 36064118. Observational study˰




Anttonen J, Remes T, Arikoski P, Lähteenmäki P, Arola M, Harila-Saari A, Lönnqvist T, Pokka T, Riikonen P, Sirkiä K, Rantala H, Ojaniemi M.
Pre- and postdiagnosis growth failure, adult short stature, and untreated growth hormone deficiency in radiotherapy-treated long-term survivors of childhood brain tumor.
PLoS One. 2022 Sep 6, 2022;17(9):e0274274. doi: 10.1371/journal.pone.0274274. PMID: 36067205. Observational study.




Del Baldo G, Carai A, Abbas R, Cacchione A, Vinci M, Di Ruscio V, Colafati GS, Rossi S, Diomedi Camassei F, Maestro N, Temelso S, Pericoli G, De Billy E, Giovannoni I, Carboni A, Rinelli M, Agolini E, Mackay A, Jones C, Chiesa S, Balducci M, Locatelli F, Mastronuzzi A.
Targeted therapy for pediatric diffuse intrinsic pontine glioma: a single-center experience.
Ther Adv Med Oncol. 2022 Sep 6, 2022;14:17588359221113693. doi: 10.1177/17588359221113693. PMID: 36090803. Observational study.




Ostrom QT, Price M, Ryan K, Edelson J, Neff C, Cioffi G, Waite KA, Kruchko C, Barnholtz-Sloan JS.
CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018.
Neuro Oncol. 2022 Sep 6, 2022;24(Supplement_3):iii1-iii38. doi: 10.1093/neuonc/noac161. PMID: 36066969. Observational study.




Rades D, Witteler J, Trillenberg P, Olbrich D, Schild SE, Tvilsted S, Kjaer TW.
Increasing Seizure Activity During Radiation Treatment for High-grade Gliomas - Final Results of a Prospective Interventional Study.
In Vivo. 2022 Sep 7, 2022;36(5):2308-2313. doi: 10.21873/invivo.12961. PMID: 36099095. Interventional study.




Horikawa M, Koizumi S, Oishi T, Yamamoto T, Ikeno M, Ito M, Yamasaki T, Amano S, Sameshima T, Mitani Y, Otani Y, Yan Y, Suzuki T, Namba H, Kurozumi K.
Potent bystander effect and tumor tropism in suicide gene therapy using stem cells from human exfoliated deciduous teeth.
Cancer Gene Ther. 2022 Sep 8. doi: 10.1038/s41417-022-00527-5. PMID: 36076062. Laboratory investigation˰




Huang X, Hansen J, Lee PC, Wu CK, Federman N, Arah OA, Li CY, Olsen J, Ritz B, Heck JE.
Maternal diabetes and childhood cancer risks in offspring: two population-based studies.
Br J Cancer. 2022 Sep 10. doi: 10.1038/s41416-022-01961-w. PMID: 36088507. Observational study.




Damodharan S, Helgager J, Puccetti D.
Indolent presentation of a diffuse midline glioma, H3 K27-altered.
Childs Nerv Syst. 2022 Sep 12. doi: 10.1007/s00381-022-05668-4. PMID: 36094605. Case report˰




Kong BY, Sim HW, Barnes EH, Nowak AK, Hovey EJ, Jeffree R, Harrup R, Parkinson J, Gan HK, Pinkham MB, Yip S, Hall M, Tu E, Carter C, Koh ES, Lwin Z, Dowling A, Simes JS, Gedye C.
Multi-Arm GlioblastoMa Australasia (MAGMA): protocol for a multiarm randomised clinical trial for people affected by glioblastoma.
BMJ Open. 2022 Sep 14, 2022;12(9):e058107
. doi: 10.1136/bmjopen-2021-058107. PMID: 36104135. Interventional study Protocol.